6:54 PM
 | 
May 09, 2014
 |  BC Extra  |  Financial News

Medivation up on Xtandi sales

Medivation Inc. (NASDAQ:MDVN) gained $5.11 to $65.11 on Friday after reporting 1Q14 results late Thursday, including U.S. sales of prostate cancer drug Xtandi enzalutamide that beat the Street's estimate. First quarter U.S. net sales of Xtandi, as...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >